Complete Blood Count Device Market to Surpass US$ 6,361.2 Million by 2028

Global Complete Blood Count Device Market, by Product Type (3-Part Analyzer, 5-Part Analyzer, and 6-Part Analyzer), by Modality (Portable and Stationary), by Test Type (White Blood Cell Count (WBC or leukocyte count), WBC Differential Count, Red Blood Cell Count (RBC or erythrocyte count), Hematocrit (Hct), Hemoglobin (Hbg), Platelet Count, Mean Platelet Volume (MPV), Mean Corpuscular Hemoglobin (MCH), and Others), by End User (Hospital, Diagnostic Laboratories, Research Institutes, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) was valued at US$ 3,642.9 Million in 2021, and is projected to exhibit a CAGR of 8.3% during the forecast period (2021-2028).

Key players operating in the market are focusing on development of technologically advanced products in order to analyze various blood components on single device, which is expected to drive the market growth over the forecast period. For instance, in June 2016, HORIBA Medical's, a medical devices company, developed Yumizen H500- Affordable 6 part Hematology Analyzer, which includes 27 parameters including complete six part differential (LMNEB+LIC), and only two reagents are required for analysis. Moreover, in December 2021, Nihon Kohden Corporation, a medical technology company, launched MEK-1305 Celltac α+, an Automated Hematology and ESR Analyzer in the global market. MEK-1305 is the world’s first hematology analyzer, which can measure complete blood count (CBC) including white blood cell 3-part differential and erythrocyte sedimentation rate (ESR) simultaneously. Furthermore, the company developed MEK-1305 based on the concept of providing rapid and accurate test results.

Global Complete Blood Count Device Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 pandemic has affected various industries globally. The players operating in the global complete blood count device market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of January 5, 2022 are about 293,750,692 confirmed cases with 5,454,131 deaths.

For instance, according to an article published by Pubmed Central in February 2021, which included a study of 90 COVID-19-positive ICU patients and 30 COVID-19-negative ICU patients. It was found that all COVID-19 patients had significant quantitative and morphologic changes in their WBCs, which differed between moderate and severe illness stages.

Therefore, COVID-19 patients in hospitals should have a daily CBC with manual WBC differential to look for numerical and morphologic alterations that could indicate a poor outcome or disease progression. The healthcare and medical device businesses will benefit from the advancement of artificial intelligence and machine learning (AI/ML), which will allow them to diagnose disease better and earlier, treat illnesses more precisely, and engage patients more effectively. With this growth comes new problems in digital healthcare, such as the price and complexity of new technology, the need for education and innovation, and cyber security.

Browse 44 Market Data Tables and 42 Figures spread through 204 Pages and in-depth TOC on “Global Complete Blood Count Device Market”-  Forecast to 2028,  Global Complete Blood Count Device Market, by Product Type (3-Part Analyzer, 5-Part Analyzer, and 6-Part Analyzer), by Modality (Portable and Stationary), by Test Type (White Blood Cell Count (WBC or leukocyte count), WBC Differential Count, Red Blood Cell Count (RBC or erythrocyte count), Hematocrit (Hct), Hemoglobin (Hbg), Platelet Count, Mean Platelet Volume (MPV), Mean Corpuscular Hemoglobin (MCH), and Others), by End User (Hospital, Diagnostic Laboratories, Research Institutes, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) – Forecast 2028

To know the latest trends and insights prevalent in the Global Complete Blood Count Device Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/complete-blood-count-device-market-4974

Key players operating in the global complete blood count device market are focusing on adoption of inorganic growth strategies such as partnerships to increase their market presence in the global market. For instance, in July 2021, Bio-Rad Laboratories, Inc. announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.

Key Takeaways of the Global Complete Blood Count Device Market:

• The global complete blood count device market is expected to exhibit a CAGR of 8.3% during the forecast period, owing to increasing incidence of chronic diseases such as lungs and heart diseases, which is expected to drive the segment growth over the forecast period. For instance, according to the National Centre for Chronic Disease Prevention and Health Promotion, report published in September 2021, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the U.S., and about 659,000 people in the U.S. die from heart disease each year.
• Among product type, 3-Part analyzer holds a dominant position in the market owing to increasing product launches. For instance, in March 2021, Sysmex Corporation, a medical devices company, launched its next-generation flagship model in the hematology field, the XR-Series Automated Hematology Analyzer, a compact 3-part WBC differential model, and the XQ-Series Automated Hematology Analyzer in the global market.
• Among modality, stationary complete blood count devices holds a dominant position in the market as they are mostly used in hospitals, diagnostics laboratories, and other large facilities to conduct multiple blood tests at a time
• Major players operating in the global complete blood count device market include Abbott Laboratories, bioMérieux SA, Danaher Corporation, Siemens Healthineers, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Sysmex Asia Pacific Pte Ltd, Becton, Dickinson and Company, Sight Diagnostics, Horiba, and Nihon Kohden Corporation